Windtree Therapeutics (WINT) announced it is targeting the planned interim analysis results for the istaroxime cardiogenic shock SEISMiC SCAI Stage C Phase 2 study for July 2025. The SEISMiC C Study is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care, including inotropes or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for six hours followed by the ability for istaroxime to allow reduction in the other inotropes and vasopressors based on the patient’s condition. The primary endpoint of the study is the systolic blood pressure profile over the first six hours of treatment. Other key study measurements include various measures of cardiac function, SBP changes at specified timepoints, the vasopressor-inotrope score, avoidance of progression to SCAI Stage D or E cardiogenic shock and need for mechanical cardiac support, time to treatment failure, arrhythmia assessments, days alive and out of the hospital through day 30, physiologic measures and length of stay in the intensive care unit and hospital.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics Inc. Reports Q1 2025 Financial Results
- Windtree Therapeutics files to sell 42.17M shares of common stock for holders
- Windtree Therapeutics reports Q1 EPS ($4.63)
- Windtree Therapeutics announces presentation highlighting istaroxime
- Windtree receives advice from IP, FDA on exclusivity strategy for istaroxime